Short Interest in Pharming Group (NASDAQ:PHAR) Declines By 47.2%

Pharming Group (NASDAQ:PHAR) saw a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 2,800 shares, a decrease of 47.2% from the February 13th total of 5,300 shares. Based on an average trading volume of 7,100 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

PHAR has been the topic of several research reports. Jefferies Financial Group started coverage on Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Tuesday, December 17th.

Pharming Group Price Performance

Shares of Pharming Group stock opened at $8.74 on Friday. The stock has a market cap of $594.59 million, a P/E ratio of -33.62 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The stock’s fifty day moving average is $9.05 and its 200 day moving average is $8.57. Pharming Group has a one year low of $6.65 and a one year high of $11.80.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Sell-side analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.